Open | $1.140 |
Close | $1.100 |
Volume / Avg. | 361.941K / 742.541K |
Day Range | 1.070 - 1.140 |
52 Wk Range | 0.740 - 1.760 |
Market Cap | $44.861M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 44 |
Short Interest | 0.13% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Achilles Therapeutics (NASDAQ: ACHL) through any online brokerage.
Other companies in Achilles Therapeutics’s space includes: NKGen Biotech (NASDAQ:NKGN), Estrella Immunopharma (NASDAQ:ESLA), Cellectar Biosciences (NASDAQ:CLRB), Bolt Biotherapeutics (NASDAQ:BOLT) and Elicio Therapeutics (NASDAQ:ELTX).
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by B of A Securities on Thursday, December 14, 2023. The analyst firm set a price target for 0.50 expecting ACHL to fall to within 12 months (a possible -54.55% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Achilles Therapeutics (NASDAQ: ACHL) is $1.1 last updated March 18, 2024 at 7:47 PM EDT.
There are no upcoming dividends for Achilles Therapeutics.
Achilles Therapeutics’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Achilles Therapeutics.
Achilles Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.